We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery.
Journal of Cardiothoracic and Vascular Anesthesia 1999 Februrary
OBJECTIVE: In the present study, the authors compared continuous infusion to bolus administration of sufentanil and midazolam in patients undergoing mitral valve surgery. The purpose of the study was to evaluate the hemodynamic variability, total dose, effective plasma drug concentrations, and simplicity of the two anesthetic techniques.
DESIGN: Prospective, randomized study.
SETTING: University hospital.
PARTICIPANTS: Thirty patients scheduled for elective mitral valve surgery.
INTERVENTIONS: Induction of anesthesia was similar in both groups and consisted of sufentanil, up to 2 microg/kg, and midazolam, 0.05 to 0.15 mg/kg, followed by atracurium, 0.5 mg/kg. Anesthesia was maintained in the bolus group with predetermined boluses of sufentanil, 2 microg/kg, and midazolam, 0.03 mg/kg. Boluses were not administered if blood pressure was within 20% of baseline. The continuous-infusion group received sufentanil, 3.6 microg/kg/h, and midazolam, 0.08 mg/kg/h, started immediately after induction. The infusion rate was reduced to sufentanil, 1.8 microg/kg/h, and midazolam, 0.04 mg/kg/h, after sternotomy and was discontinued at skin closure. Atracurium was infused at a rate of 0.5 mg/kg/h up to sternal closure in both groups. No inhalation agents were used.
MEASUREMENTS AND MAIN RESULTS: Hemodynamic variability between the groups was not significant. Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01). Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively. There were 3.46 (range, 0 to 7) additional bolus injections in the bolus group and 0.31 (range, 0 to 1) in the continuous-infusion group (p < 0.001). Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL). Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).
CONCLUSION: The simplicity of the continuous infusion is a major advantage. This technique provides hemodynamically safe and stable conditions similar to those of bolus administration.
DESIGN: Prospective, randomized study.
SETTING: University hospital.
PARTICIPANTS: Thirty patients scheduled for elective mitral valve surgery.
INTERVENTIONS: Induction of anesthesia was similar in both groups and consisted of sufentanil, up to 2 microg/kg, and midazolam, 0.05 to 0.15 mg/kg, followed by atracurium, 0.5 mg/kg. Anesthesia was maintained in the bolus group with predetermined boluses of sufentanil, 2 microg/kg, and midazolam, 0.03 mg/kg. Boluses were not administered if blood pressure was within 20% of baseline. The continuous-infusion group received sufentanil, 3.6 microg/kg/h, and midazolam, 0.08 mg/kg/h, started immediately after induction. The infusion rate was reduced to sufentanil, 1.8 microg/kg/h, and midazolam, 0.04 mg/kg/h, after sternotomy and was discontinued at skin closure. Atracurium was infused at a rate of 0.5 mg/kg/h up to sternal closure in both groups. No inhalation agents were used.
MEASUREMENTS AND MAIN RESULTS: Hemodynamic variability between the groups was not significant. Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01). Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively. There were 3.46 (range, 0 to 7) additional bolus injections in the bolus group and 0.31 (range, 0 to 1) in the continuous-infusion group (p < 0.001). Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL). Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).
CONCLUSION: The simplicity of the continuous infusion is a major advantage. This technique provides hemodynamically safe and stable conditions similar to those of bolus administration.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app